Category: Pharmacy - Page 2

Therapeutic equivalence in combination drugs isn't as simple as matching active ingredients. Dose differences, inactive ingredients, and narrow therapeutic index drugs can lead to dangerous errors. Learn how to manage substitutions safely.

Prior authorization for NTI drugs often delays life-saving medications despite clinical evidence showing generics can be dangerous. Learn why insurers require brand-name versions and what patients can do to get faster access.

Pharmacists must clearly explain generic medications to patients to prevent confusion, improve adherence, and avoid dangerous misunderstandings. Learn the essential counseling points backed by law and evidence.

Medication errors kill thousands every year in hospitals and clinics - but most are preventable. Learn how high-alert drugs, barcode systems, and patient involvement are reducing harm and saving lives.

The Hatch-Waxman Amendments of 1984 created the modern generic drug industry by letting companies approve cheaper versions of brand-name drugs without repeating clinical trials. It balanced innovation incentives with faster access to affordable medicines.

Fasted and fed state testing reveal how food affects drug absorption and exercise performance. Understanding both conditions is critical for safe medication use and effective training. Neither state is universally better-context determines the right choice.

Generic drug shortages are rising due to fragile supply chains, low profit margins, and overreliance on foreign manufacturing. Learn why essential medications keep disappearing-and what’s being done to fix it.

Learn how to tell the difference between manufacturer expiration dates and pharmacy beyond-use dates for compounded medications. Know when your medicine is still safe-and when it’s not.

Steroid eye drops reduce inflammation quickly but carry serious risks like glaucoma and cataracts if used too long. Learn how to use them safely with proper monitoring and when to seek help.

Patent law protects pharmaceutical innovation by granting exclusive rights to drug developers, but also enables affordable generics through the Hatch-Waxman Act. This system balances R&D incentives with public access, saving billions annually while facing challenges like evergreening and patent thickets.